Malignant fibrous histiocytoma a retrospective study of 167 cases

Abstract

A retrospective study of 167 patients with soft-tissue malignant fibrous histiocytoma of the trunk, extremities, and retroperitoneal region revealed twice as many deeply situated tumors as superficial tumors. Malignant fibrous histiocytoma may be subclassified into fibrous, giant-cell, myxoid, and inflammatory variants. The fibrous variant accounted for two-thirds of the lesions. The prognosis is no different among the histologic subtypes. The depth of the tumor significantly affects survival, and three important groups were identified: superficial tumors, superficial tumors that recur in deep locations, and deeply situated tumors. The group with superficial tumors that subsequently did not recur in deep locations had a significantly better 4-year survival rate than did the other two groups (65% versus 34% and 40%, respectively). Patients with distally located tumors had a better 5-year survival rate than did patients with proximally located tumors (73% versus 28%). Local recurrence was found in 51% of patients who had a "complete" excision. Patients with superficial tumors had a higher local recurrence rate (71%) than did those with deep tumors (41%). Few patients with retroperitoneal tumors were long-term survivors; the 5-year survival rate was 14%. Cancer 45167-178. 1980. ALIGNANT FIBROUS HISTIOCYTOMA is one of a

Primary pulmonary malignant fibrous histiocytoma mimics pulmonary artery aneurysm with partial thrombosis: various radiologic evaluations

“…MFH is a primitive sarcoma from the deep soft tissues and is postulated to be of both fibrotic and histiocytic mesenchymal cell origin [2][3][4]. There are five histologic subtypes of MFH, including storiform/pleomorphic type (most common), myxoid type, giant cell type, inflammatory type and angiomatoid type.…”

Primary malignant fibrous histiocytoma of the kidney: report of a case and literature review

“…[13,20] If local infiltration or distant metastases are present, treatment with polychemotherapy may be indicated, although the effectiveness is questionable and the response rate is only 33%. [26] The overall prognosis is poor, and the 5-year survival rate is less than 14%. [12] The present case demonstrated recurrence and metastases postoperatively within five and eight months, respectively, and despite polychemotherapy, the patient died of disease within the first postoperative year.…”

Malignant fibrous histiocytoma in a patient presenting with urinary system symptoms

“…Five-year survival rate is 66% when tumor dimension is less than 5 cm, decreasing to 30% if the diameter is greater than 5 cm. 3,10 Similarly, there is a positive correlation between tumor diameter and rate of metastasis. Prognosis is better in tumors located in extremities compared to retroperitoneal or deeply located tumors.…”

“…Prognosis is better in tumors located in extremities compared to retroperitoneal or deeply located tumors. 9,10 Primary treatment of MFH is surgical excision of the mass. Radiotherapy plays an important role in the postsurgical treatment; however, the efficacy of chemotherapy is controversial.…”

“…Radiotherapy plays an important role in the postsurgical treatment; however, the efficacy of chemotherapy is controversial. 10 references…”